GlassScriptPhysician profile
Laurel A Stadtmauer
NPI 1477520054
$21,135.69
in general payments reported to CMS, 2019-2025
14 companies · $3,333 in 2025
The $3,333 reported for 2025 was more than what 94% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,899 · 2020: $36.72 · 2021: $1,391 · 2022: $6,350 · 2024: $127 · 2025: $3,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,284 · Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,284.00 |
| Food and Beverage | $175.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $9,114.30 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $7,362.68 | 2019-2025 | Menopur |
| Organon LLC | $3,284.00 | 2025 | Nexplanon |
| Abbvie INC. | $519.72 | 2019-2022 | |
| Emd Serono, INC. | $220.06 | 2019-2025 | |
| Intuitive Surgical, INC. | $215.80 | 2019 | |
| Hologic Sales and Service, LLC | $155.79 | 2022 | |
| Coopersurgical, INC. | $147.89 | 2019-2021 | |
| Asensus Surgical, INC. | $46.67 | 2021 | |
| Galen US INC | $31.54 | 2019 | |
| Pfizer INC. | $21.96 | 2022 | |
| Myovant Sciences INC. | $15.28 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Stadtmauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.